Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 14,147 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Schizophrenia
Interventions: Emraclidine 15 mg, Emraclidine 30 mg, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 19
States / cities: Bentonville, Arkansas • Bellflower, California • La Habra, California + 15 more

Conditions: Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral
Interventions: Fostamatinib, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Orange, California • Washington D.C., District of Columbia • Hialeah, Florida + 6 more

Conditions: Bipolar Disorder, Manic
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 23
States / cities: Rogers, Arkansas • Bellflower, California • Culver City, California + 18 more

Conditions: Osteo Arthritis Knee
Interventions: V120083, Naproxen, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 30
States / cities: Birmingham, Alabama • Tuscumbia, Alabama • North Hollywood, California + 24 more

Conditions: Healthy
Interventions: SRX251; Drug
Lead sponsor: Azevan Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Hypertension
Interventions: Azilsartan medoxomil and olmesartan, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 80
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 77 more

Conditions: Obstructive Sleep Apnea, Hypertension
Interventions: Lorundrostat, Placebo; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 27
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more

Conditions: Chemotherapy Exposure, Handling Guidelines, Oncology Nurse, Adherence
Interventions: The Workplace program to Improve the Safe Handling of hazardous drugs (WISH); Behavioral
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Attention-deficit/Hyperactivity Disorder
Interventions: Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 81
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more

Conditions: Polypharmacy, Insomnia, Anticoagulants
Interventions: Academic Detailing (AD), LEAP; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Coronary Syndrome
Interventions: Apolipoprotein A-I [human] (apoA-I), Placebo; Biological · Other
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 18,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 202
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more

Conditions: Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions: NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 299
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more

Conditions: Schizophrenia
Interventions: AMG 579, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Parkinson's Disease, Healthy
Interventions: BIIB054, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Hallandale, Florida • Oviedo, Florida + 6 more

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: TZP-102, Placebo; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 8 more

Conditions: Low Back Pain
Interventions: Hydrocodone ER, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 87
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 71 more

Conditions: Healthy Volunteers
Interventions: LY3023703, Placebo, Celecoxib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis, Spinal Cord Injuries, Cervical Spinal Cord Injury, Tetraplegic; Paralysis, Quadriplegia/Tetraplegia
Interventions: Intervention/Treatment; Device
Lead sponsor: Synaptrix Labs Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: D-Tagatose; Drug
Lead sponsor: Robert Lodder; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Garden Grove, California • Miami, Florida • Atlanta, Georgia + 2 more

Conditions: Eosinophilic Esophagitis
Interventions: QAX576 placebo, QAX576; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Stanford, California • Chicago, Illinois • Minneota, Minnesota + 2 more

Conditions: Smoking Cessation
Interventions: placebo, varenicline; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Litchfield Park, Arizona • Los Angeles, California • Santa Ana, California + 9 more

Conditions: Type 1 Diabetes, Pregnancy
Interventions: Automated Insulin Delivery; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Santa Barbara, California • Rochester, Minnesota • New York, New York

Conditions: Macular Edema, Branch Retinal Vein Occlusion
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more

Conditions: Healthy Volunteer
Interventions: AG-348, Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee

Safety Study of SRX251 Capsules in Healthy Female Volunteers

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

Promoting Adherence to Chemotherapy Handling Guidelines Among Oncology Nurses

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

MIDAS Cluster Randomized Controlled Trial of Implementation Strategies to Optimize Use of Medications in VA Clinical Settings

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

A Single Dose Study of LY3023703 in Healthy Participants

EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis

A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)

Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis

Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date

Automated Insulin Delivery in Pregnant Patients With Type 1 Diabetes With Extension Into Outpatient at Home

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

A Phase I Study of AG-348 in Healthy Volunteers